行情

KIN

KIN

Kindred Bio
NASDAQ

实时行情|Nasdaq Last Sale

9.30
-0.20
-2.11%
盘后: 9.30 0 0.01% 16:00 01/27 EST
开盘
9.37
昨收
9.50
最高
9.56
最低
9.30
成交量
8.09万
成交额
--
52周最高
11.35
52周最低
5.96
市值
3.63亿
市盈率(TTM)
-5.6597
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

KIN 新闻

  • Acceleron肺高压药物试验达到主要目标 股价暴涨79%
  • 新浪财经.1小时前
  • 英国超市巨头承诺投10亿英镑 到2040年实现零排放
  • 新浪财经.1小时前
  • 韩国政府:将全力以赴抗击疫情并稳定金融市场
  • 新浪财经.2小时前
  • 美国父母的儿童早教支出每年高达420亿美元
  • 新浪财经.2小时前

更多

所属板块

生物技术和医学研究
-0.88%
制药与医学研究
-0.51%

热门股票

名称
价格
涨跌幅

KIN 简况

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
展开

Webull提供Kindred Biosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。